Literature DB >> 15322246

Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.

Sonnet J H Arlander1, Maoqing Dong, Xi-Qin Ding, Delia I Pinon, Laurence J Miller.   

Abstract

The molecular basis of docking of receptor ligands having differences in biological activity and their subsequent effects on receptor conformation represent areas of great interest. In this work, we focus on the sulfated tyrosyl residue in position 27 of cholecystokinin (CCK) and its spatial approximation with the type A CCK receptor residue Arg(197) that has been predicted from mutagenesis experiments. We have examined the requirement for sulfation of this residue in a series of structurally related peptide agonists, partial agonists, and antagonists using assays of receptor binding and biological activity. Whereas sulfation of CCK position 27 was critical for affinity and potency of a full agonist, it had progressively less effect as the biological activity of the ligand was reduced. It had an intermediate effect on the partial agonist and no effect on the antagonist. In addition, photoaffinity labeling was used to determine the spatial approximations between the receptor and residue 27 of the agonist and antagonist in this series. Direct photoaffinity labeling with a full agonist probe confirmed the spatial approximation of ligand residue 27 and receptor residue Arg(197) in the active complex. Of note, the analogous antagonist probe labeled a distinct region within the receptor amino terminus, confirming a key structural difference in active and inactive complexes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322246     DOI: 10.1124/mol.104.001396

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor.

Authors:  Jérôme Hénin; Bernard Maigret; Mounir Tarek; Chantal Escrieut; Daniel Fourmy; Christophe Chipot
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

2.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

3.  Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction.

Authors:  Maoqing Dong; Xi-Qin Ding; Scott E Thomas; Fan Gao; Polo C-H Lam; Ruben Abagyan; Laurence J Miller
Journal:  Biochemistry       Date:  2007-03-24       Impact factor: 3.162

4.  Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Ruben Abagyan; Laurence J Miller
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

5.  Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.

Authors:  Aditya J Desai; Polo C H Lam; Andrew Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  J Med Chem       Date:  2015-12-10       Impact factor: 7.446

6.  Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Fan Gao; Delia I Pinon; Laurence J Miller
Journal:  Biochemistry       Date:  2008-08-13       Impact factor: 3.162

7.  Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.

Authors:  Maoqing Dong; Laurence J Miller
Journal:  Peptides       Date:  2013-06-14       Impact factor: 3.750

Review 8.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.